|Articles|January 2, 2004
- Pharmaceutical Technology-01-02-2004
- Volume 28
- Issue 1
The Bioterrorism Act
Author(s)Arthur J. Falk, PhD
Two FDA final rules issued in response to the Bioterrorism Response Act of 2002 may significantly affect the supply and importation of pharmaceutical excipients.
Advertisement
Articles in this issue
over 22 years ago
Coprocessed Excipients for Solid Dosage Formsover 22 years ago
Manufacturing Execution Systemsover 22 years ago
State-of-the-Art Packaging Machinesover 22 years ago
January 2004over 22 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersover 22 years ago
New Supply-Chain Dynamicsover 22 years ago
In the Spotlight--February 2004over 22 years ago
January 2004Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data
2
Can AI Fix Pharma's Last-Mile Delivery Blind Spot?
3
Everything to Know about BMS & NVidia’s AI Supercomputer
4
Midyear 2026 Check-In: Megha Sinha on Pharma's AI Skills Gap
5
